Methods for Detecting Nucleic Acid Variants
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 62/971,530, filed Feb 7, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,437,839 | Methods for Detecting Nucleic Acid Variants In force · Medium confidence | Ultima Genomics, Inc. | In force | Medium confidence | ||
| US 12,482,536 | Methods for Detecting Nucleic Acid Variants In force · High confidence | Ultima Genomics, Inc. | In force | High confidence | ||
| US 11,763,915 | Methods for Detecting Nucleic Acid Variants In force · High confidence | Ultima Genomics, Inc. | In force | High confidence | ||
| Application 16/875,645 | Methods and Systems for Detecting Residual Disease Abandoned Abandoned Oct 16, 2024 | Ultima Genomics, Inc. | Abandoned | Abandoned Oct 16, 2024 | ||
| Application 18/910,965 | Methods and Systems for Detecting Residual Disease Pending Not granted | Ultima Genomics, Inc. | Pending | Not granted | ||
| Application 19/324,558 | Methods for Detecting Nucleic Acid Variants Pending Not granted | Ultima Genomics, Inc. | Pending | Not granted | ||
| Application 19/367,611 | Methods for Detecting Nucleic Acid Variants Pending Not granted | Ultima Genomics, Inc. | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Ultima Genomics, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.